Astellas Completes OSI Acquisition; Shares Jump In Tokyo
This article was originally published in PharmAsia News
Executive Summary
Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding
You may also be interested in...
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
Astellas outlines its growth strategy, offering ways the company plans to overcome the sales loss of U.S. patent expiries for blockbusters Prograf (tacrolimus) and Harnal (tamsulosin).